

SSSCA1 Antibody (N-term) Blocking peptide

Synthetic peptide Catalog # BP13654a

Specification

SSSCA1 Antibody (N-term) Blocking peptide - Product Information

Primary Accession

060232

SSSCA1 Antibody (N-term) Blocking peptide - Additional Information

Gene ID 10534

Other Names

Sjoegren syndrome/scleroderma autoantigen 1, Autoantigen p27, SSSCA1

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13654a was selected from the N-term region of SSSCA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SSSCA1 Antibody (N-term) Blocking peptide - Protein Information

Name ZNRD2 (HGNC:11328)

Function

Might play a role in mitosis. Antigenic molecule. Could be a centromere-associated protein. May induce anti-centromere antibodies.

SSSCA1 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

SSSCA1 Antibody (N-term) Blocking peptide - Images

SSSCA1 Antibody (N-term) Blocking peptide - Background







This antigen is recognized by a subset of anti-centromereantibodies from patients with scleroderma and/or Sjogren'ssyndrome. Subcellular localization has not yet been established.

SSSCA1 Antibody (N-term) Blocking peptide - References

Shen, A., et al. Neurosurgery 65(1):153-159(2009)Matsuoka, S., et al. Science 316(5828):1160-1166(2007)Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007) :Suzuki, H., et al. Genome Res. 11(10):1758-1765(2001)Muro, Y., et al. Clin. Exp. Immunol. 111(2):372-376(1998)